Traws Pharma
TRAW
9 hedge funds and large institutions have $2.81M invested in Traws Pharma in 2015 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
25% less funds holding
Funds holding: 12 → 9 (-3)
52% less capital invested
Capital invested by funds: $5.79M → $2.81M (-$2.98M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$164K |
| 2 |
Goldman Sachs
New York
|
+$164K |
| 3 |
Renaissance Technologies
New York
|
+$164K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$164K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.82M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$165K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$164K |
| 4 |
D.E. Shaw & Co
New York
|
-$164K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$164K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2 | – | – | – |
|
|
GPP
27
Great Point Partners
Greenwich,
Connecticut
| – | -$1.82M | -10 | Closed |
|
|
AFM
28
Anson Funds Management
Dallas,
Texas
| – | -$165K | -1 | Closed |
|
29
Millennium Management
New York
| – | -$117K | -1 | Closed |
|
|
ARTA
30
A.R.T. Advisors
New York
| – | -$59K | – | – |
|
31
Dimensional Fund Advisors
Austin,
Texas
| – | -$22K | – | – |
|
|
PP
32
Paloma Partners
Greenwich,
Connecticut
| – | -$64K | – | – |
|
33
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$4K | – | – |
|
TRAW Hedge Fund Activity: Q1 2015 in Review
9 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2015, worth a combined $2.81M — down 52% from $5.79M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TRAW and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $164K. The largest seller was Great Point Partners, exiting entirely with an estimated $1.82M sold.
- 9 institutional investors held Traws Pharma (TRAW) as of Q1 2015, down from 12 in Q4 2014.
- Funds reported $2.81M of Traws Pharma stock for Q1 2015, down 52% quarter-over-quarter.
- 2 funds opened new Traws Pharma positions in Q1 2015 and 5 closed out, a net change of -3 holders.
- The largest Traws Pharma buyer in Q1 2015 was BlackRock Fund Advisors, an estimated $164K added.
- The largest Traws Pharma seller in Q1 2015 was Great Point Partners, an estimated $1.82M sold.
Based on aggregated 13F filings for Q1 2015.